From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search
Monoclonal antibody
TypeWhole antibody
TargetAngiopoietin 2
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
CAS Number
  • none
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass144.9 kg/mol g·mol−1

Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2.[1] As of May 2017, it is in Phase II clinical trials for the treatment of diabetic macular edema.[2][3]

This drug is being developed by Regeneron Pharmaceuticals.


  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab, American Medical Association.
  2. Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at
  3. Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at


Nesvacumab is part of WikiMD's free ^articles!

^Nesvacumab (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Overweight?. W8MD's physician weight loss & sleep medicine program can HELP. Philadelphia lose weight. NYC lose weight Tele weight loss available